The present study examined if hypoxia causes free radical-mediated disruption of the blood-brain barrier (BBB) and impaired cerebral oxidative metabolism and whether this has any bearing on neurological symptoms ascribed to acute mountain sickness (AMS). Ten males provided blood samples from the internal jugular vein and radial artery during normoxia and during 9h passive exposure to hypoxia (12.9% O 2 ). Cerebral blood flow was determined via the Kety-Schmidt technique with net exchange calculated by the Fick Principle. AMS and headache was determined using clinically-validated questionnaires. Electron paramagnetic resonance spectroscopy and ozone-based chemiluminescence were employed for the direct detection of spin-trapped free radicals and nitric oxide (NO) metabolites. Neuron-specific enolase (NSE), S100β, and 3-nitrotyrosine (3-NT) were determined by ELISA. Hypoxia increased the arterio- ) free radicals and lipid hydroperoxides (P < 0.05 vs. normoxia) that correlated with the increase in AMS/headache scores (r = -0.50 to -0.90, P < 0.05). This was associated with a reduction in the a-v D and hence net cerebral uptake of plasma nitrite and increased cerebral output of 3-NT (P < 0.05 vs. normoxia) that also correlated against AMS/headache scores (r = 0.74 to 0.87, P < 0.05). In contrast, hypoxia did not alter the cerebral exchange of S100β and both global cerebral oxidative metabolism (CMRO 2 ) and neuronal integrity (NSE) remained preserved (P > 0.05 vs. normoxia). In conclusion, these findings indicate that hypoxia stimulates cerebral oxidative-nitrative stress which has broader implications for other clinical models of human disease characterized by hypoxemia. This may prove a risk factor for AMS by a mechanism that appears independent of impaired BBB function and cerebral oxidative metabolism.
INTRODUCTION
Cellular hypoxia due to systemic hypoxemia is considered a fundamental mechanism of vascular injury in the critically ill since it is typically accompanied by oxidative-inflammatory stress. It can predispose to the systemic inflammatory response syndrome (SIRS) that ultimately leads to major organ dysfunction and failure (16). Likewise, failure to adapt adequately to the albeit acute inspiratory hypoxia encountered during rapid ascent to high-altitude can also result in hypoxemia, oxidative-inflammatory stress and neurological complications in the otherwise healthy individual. This may prove a useful non-clinical correlate that may provide alternative, indeed unique insight into the putative mechanisms underlying oxidative-inflammatory disease (21).
One such neurological complication encountered as a function of inadequate acclimatization to hypoxia is acute mountain sickness (AMS), a syndrome characterized by headache and associated vegetative symptoms typically encountered within 6-12h following rapid ascent above 2500m (48) . Diffusion-weighted magnetic resonance imaging (DW-MRI) studies suggest that AMS is a mild form of high-altitude cerebral oedema (HACE) characterized by intracellular (cytotoxic) superimposed upon mild extracellular (vasogenic) oedema caused by subtle disruption of the blood-brain barrier (BBB) (28, 42) . Though controversial (8) , direct activation of the trigeminovascular system (TVS) subsequent to displacement of pain-sensitive unmyelinated fibres caused by intracranial hypertension (ICH) is considered the primary stimulus responsible for cephalalgia (41).
The precise mechanisms responsible for intracellular swelling and barrier disruption in hypoxia are largely unknown. Hypoxia increases the systemic accumulation of free radicals which may have important implications for the brain and underlying cerebrovascular endothelium since they are especially vulnerable to peroxidative stress (4, 25) . Free radicals may cause direct structural damage to the BBB microvascular endothelium, neurons and glia (14) and promote cell swelling through down-regulation of Na Therefore, the primary aim of the current study was to document the trans-cerebral exchange kinetics of oxidative-nitrative stress biomarkers in response to inspiratory hypoxia for the first time in healthy humans. Our secondary aim was to determine if cerebral exchange was associated with symptoms of AMS subsequent to alterations in the structural integrity of the BBB and cerebral oxidative metabolism. We hypothesized that compared to normoxia, hypoxia would promote the cerebral formation and net release of metal-catalyzed lipid-derived free radicals and associated peroxidants across the cerebrovascular bed (oxidative stress) as indicated (34) . In terms of our secondary aim, we hypothesized that free radical output would correlate against AMS symptom scores subsequent to focal barrier disruption reflected by an increased jugular venous outflow and net cerebral output of S100β whose appearance specifically reflects on-going failure of the BBB independent of structural neuronal/brain tissue damage (29) . Finally, we expected free radical-mediated disruption of the BBB to compound cerebral hypoxia due to the extravascular accumulation of edema thus shifting cerebral oxidative metabolism towards the glycolytic and depressing the cerebral metabolic rate of oxygen (CMRO 2 ).
MATERIALS AND METHODS

Ethical approval
The study was approved by the Ethics Committees of Copenhagen and Frederiksberg (KF01-290/011). All procedures complied with those outlined by the Declaration of Helsinki.
Subjects
Eleven healthy males aged 27 ± 4 (mean ± SD) years old volunteered for the study. Specific exclusion criteria included any history of chronic daily headache, habitual antioxidant vitamin or anti-inflammatory supplementation, smoking or underlying cardiovascular, cerebrovascular, or respiratory disease infection and any symptoms suggestive of an infectious illness during the fortnight preceding the study.
Experimental design
Subjects were instructed to attend the laboratory at 07:00h following a 12h overnight fast.
Catheters were placed under local anesthesia (1% lidocaine) in the radial artery (BD Arterial Cannula with FloSwitch™, 20G/1.10mm x 45mm) and right internal jugular vein (Arrow™ Central Venous Catheterization Set, 18GA, 20cm) via ultrasound guidance with the tip pointing cranially for the purposes of blood sampling and invasive measurement of (mean) arterial blood pressure (MAP). Following 30 min of supine rest, paired arterial and venous samples were obtained simultaneously in normoxia (21%O 2 ) and following 9h passive exposure to normobaric hypoxia (12.9%O 2 ) which corresponds to a simulated altitude of ≈3800m for the measurement of hemodynamic and metabolic parameters. The respective inspirates were achieved by connecting each subject through a tight-fitting mask with a non-rebreathing valve to medical grade quality gas directed from compressed gas cyclinders into a 500L meteorological balloon at the prevailing barometric pressure (ie. normobaric challenges).
Measurements
Acute mountain sickness
AMS was assessed using the Lake Louise (LL-cumulative self report + clinical score) (37) and Environmental Symptoms Questionnaire Cerebral (ESQ-C)(40) scoring systems and a visual analogue scale (VAS) was employed to examine headache (26) . 
Haemodynamic parameters
Trans-cerebral exchange kinetics
Immediately following the measurement of CBF, paired whole blood samples were simultaneously drawn and centrifuged at 600g (4°C) for 10 minutes. Serum, plasma and red blood cells (RBC) were immediately frozen in liquid nitrogen (-196°C ) and stored at -80°C.
Samples were left to defrost at 21ºC in the dark for 5min prior to analysis. Global CBF was converted to cerebral plasma flow (CPF) by multiplying against (1-Hct) to calculate transcerebral exchange kinetics of plasma/serum-borne metabolites according to the Fick Principle:
The cerebral net exchange of RBC-bound nitric oxide (NO) metabolites was calculated as:
Cerebral exchange (g/min) = (CBF x Hct) x a-v D By convention, a positive value indicates net influx (uptake) whereas a negative value indicates net efflux (output) across the brain.
Oxidative stress:
Lipid-derived free radicals: The electron paramagnetic resonance (EPR) spectroscopic detection of serum α-pheyl-tert-butylnitrone (PBN-adducts) was employed for the direct molecular detection of lipid-derived free radicals (7) . Briefly, 4.5mL of whole blood was added to a 6mL 50G scan width for 10 cumulative scans. EPR spectral parameters were obtained using commercially available software (Bruker Win EPR System, Version 2.11) and filtered identically. The average spectral peak-to-trough line height was considered a measure of the relative spin-adduct concentration following conformation of peak-to-trough line-width conformity and double-integration on selected samples. Nuclear hyperfine coupling constants (HCC) were confirmed following computer simulation using SimEPR32 software (1). The intra/inter-assay CV was <15% respectively.
Lipid hydroperoxides (LOOH):
Serum LOOH was determined using the ferrous iron/xylenol orange (FOX) assay (49) with modification. The intra/inter-assay CV was <2% and <4% respectively.
Antioxidants: For ascorbic acid measurements, plasma was stabilized and deproteinated by adding 900μL of 5% metaphosphoric acid (Sigma Chemical, Dorset, UK) to 100 μL K-EDTA plasma. Ascorbic acid was subsequently assayed by fluorimetry based on the condensation of dehydroascorbic acid with 1,2-phenylenediamine (47). Concentrations of α/γ-tocopherol, α/β-carotene, retinol, lycopene, zexanthin, β-cryptoxanthin and lutein were determined using an HPLC method (13, 46) . The intra and inter-assay CV were both <5%.
Nitrative stress:
Ozone-based chemiluminescence (OBC Model 280i, NOA ® , Sievers, Boulder, CO, USA), arguably the most sensitive technique for the molecular detection of NO in human blood was employed for the detection of plasma and RBC-bound NO metabolites.
Plasma: Samples (20µL) were analyzed for the total concentration of plasma NO [nitrate (NO respectively.
Brain-specific proteins:
S100β and neuron specific enolase (NSE): Serum S100β and NSE were incorporated as molecular biomarkers of "BBB-leakage" and "neuronal-parenchymal damage" respectively (29) using commercially available ELISA kits (S100β: BioVendor, Cat # RD 192090100R/NSE:
CanAg, Ref 420-10). The lower detection limits were 5ng/L and <1µg/L respectively with intra/inter-assay CV's both <5% for S100β and both <5% for NSE. Since hemolysis can confound the interpretation of NSE data (and indeed all redox-reactive biomarkers), a hemolysis index (HI) was determined for all blood samples (HI < 15 reflects no detectable hemolysis).
Statistical analysis
A prospective power calculation was performed to detect a "physiologically significant" presented as mean ± SD. When Hypoxia is indicated to be different to Normoxia (< or >, Condition main effect), this reflects a pooled (Arterial + Venous) difference (P < 0.05).
Likewise, when Venous is indicated to be different to Arterial (Sample site main effect), this reflects a pooled (Normoxia + Hypoxia) difference (P < 0.05).
RESULTS
Subject compliance:
Owing to technical failure and our inability to obtain a normoxic baseline (global) CBF reading, one subject was discarded from the overall analysis since this prevented subsequent calculation of exchange kinetics. His exclusion did not alter the qualitative (group) outcome of the remaining analyzes performed.
AMS and headache:
Hypoxia induced symptoms of AMS (LL: 3 ± 2 vs. normoxia: 0 ± 0 points, P < 0.05; ESQ-C: 0.803 ± 0.674 vs. normoxia: 0.000 ± 0.000 arbitrary units, P < 0.05) and an increase in corresponding headache scores (VAS: 29 ± 23 vs. normoxia: 0 ± 0 mm, P < 0.05).
The increase in the VAS score was inversely related to the decrease in PaO 2 (r = -0.65, P < 0.05). Brain-specific proteins: Hypoxia was associated with a general increase in the plasma concentration of S100β whereas that of NSE decreased ( Table 4 ). The net cerebral output of S100β and uptake of NSE observed during normoxia remained unchanged during hypoxia. The increased arterial concentration of S100β correlated directly with the increase in AMS and headache scores during hypoxia (LL: r = 0.88, P < 0.05; ESQ-C: r = 0.83, P < 0.05; VAS: r = 0.77, P < 0.05).
Cerebral hemodynamics and oxidative metabolism:
Retrospective power calculations:
Visual inspection of several metabolic parameters revealed potential main and interaction effects that may have escaped detection (P > 0.05) in light of insufficient power despite our best efforts to perform a (prospective) power calculation.
Retrospective analyzes for plasma ascorbate, α-tocopherol, total NO, NO
•
DISCUSSION
This study provides unique insight into the trans-cerebral exchange kinetics of free radicals and associated biomarkers of oxidative-nitrative stress during hypoxia in healthy humans. In spite of a prospective power calculation, retrospective analyzes revealed that for the most part, the study was adequately "powered" to detect main effects, but at times, less sensitive for interaction effects. In spite of this and consistent with our original hypothesis, hypoxia increased the net cerebral output of secondary lipid-derived free radicals that correlated against symptom scores of cephalalgia. The reduced vascular bioavailability of plasma NO metabolites and net cerebral output of 3-NT that also correlated against symptom scores provides clear evidence for increased cerebral nitrative stress. In contrast, hypoxia did alter the cerebral exchange of S100β indicating that the BBB remained largely intact. Furthermore, there was no molecular evidence for structural neuronal-parenchymal damage and cerebral oxidative metabolism also remained preserved. These findings provide direct evidence for increased cerebral oxidative-nitrative stress during hypoxia that may predispose to AMS by a mechanism that appears to be independent of barrier disruption and impaired cerebral oxidative metabolism. Since arterial hypoxemia is common to various diseases of the cardiovascular, pulmonary and cerebral circulation, these findings may provide useful (clinical) insight into mechanisms underlying vascular oxidativeinflammatory disease in the critically ill.
Free radical metabolism
Hypoxia has been shown to promote systemic free radical formation though the brain's contribution has not previously been quantified since reactive biomarkers have traditionally been In support, we recently detected parallel increases in mitochondrial UQ to consider ex-vivo (neutrophil) NADPH oxidase inhibition using eg. ethyl-gallimidate during the incubation phase to examine this possibility. Given the reactivity of ROS and complexity of blood as a biological matrix, a precise understanding of the source(s) and mechanism(s) that promote in-vivo oxidation during hypoxia remains a formidable challenge.
The primary species LO
• is capable of reacting at diffusion-controlled rates (k ≈ 10 9 M/s) with NO to yield peroxynitrite (33) which in turn promotes nitration of protein tyrosine residues to form 3-NT, a molecular "footprint" of nitrative stress (34) . Consistent with our previous observations (4), hypoxia favoured the intra-erythrocytic formation of NO at the expense of a reduction in systemic plasma-borne metabolites. The decreased arterial concentration of NO (27) . While the precise mechanisms responsible for the delivery of NO from its metabolites to the hypoxic cerebrovasculature remain controversial, the observed loss of NO
and systemic-cerebral formation of intra-erythrocytic NO may represent bioactive sources of NO that mediate vasodilation and strive to preserve cerebral oxidative metabolism in the face of prevailing hypoxemia.
Consistent with previous observations confined to the systemic venous circulation (4), linear relationships were observed between the increased cerebral output of oxidative-nitrative stress biomarkers and symptom scores. A conservative interpretation of this finding is that the rate of output of these biomarkers was related to the degree of arterial hypoxemia and that subjects with AMS are typically more hypoxemic than those without AMS at any given (hypoxic) F I O 2 .
However, it is also conceivable that these noxious bio-molecules may have sensitized perivascular sensory nerves and activated trigeminovascular nocioceptors to cause headache (41). In this sense, they may prove more sensitive "migraine-molecules" than other classical biomarkers such as calcitonin gene related peptide (CGRP) which is not released by the hypoxic brain even during severe AMS (8) .
BBB integrity and cerebral hemodynamics
Release of the astrocytic protein S100β to the systemic circulation correlates directly with the extent and temporal sequence of BBB opening as confirmed by contrast-enhanced MRI and its systemic appearance is thus considered a molecular surrogate of barrier integrity (29) . In the current study, we measured both S100β in combination with the neuronal protein NSE to distinguish potential barrier defects from structural brain tissue damage incurred during hypoxia.
Our findings are the first to demonstrate that the healthy brain releases S100β during normoxia suggesting that glial synthesis and extravasation reflects the "normal physiological response" even when the BBB is presumably intact and fully functional. Somewhat unexpectedly, hypoxia increased the arterial and jugular venous concentration of S100β even though the a-v D and net cerebral output remained unchanged. This suggests at least at the time of sampling, that the cerebrobvascular bed per se did not contribute to the systemic accumulation of S100β, which, in the absence of a jugular venous sample, would traditionally be interpreted as molecular evidence for subtle barrier disruption (29) . In addition to astroglial and Schwann cells, "extracerebral" sources such as adipose and skeletal tissue also express S100β (50). We therefore consider it quite unlikely that the weak correlations observed between the increased arterial concentration of S100β and AMS scores (up to 40% of the variance unaccounted for) reflects a causal relationship and further emphasizes the interpretive significance of a-v sampling.
These findings confer with previous obervations albeit confined to the systemic circulation and CSF (4, 7) and more recently, structural DW-MRI data (28, 42) . Despite being comparatively long(er)-lived secondary reactants, the LO
• -LC
• detected are none-the-less thermodynamically capable of initiating cellular membrane peroxidation (ΔE O´ ≈ +1000-1300mV vs. PUFA-H/PUFA-OOH)(11) and structural destabilization as indicated by previous reports of compromized (sarcolemmal) membrane permeability (9) . Thus, in combination with nitrative stress, these species have the potential to compromize the microvascular integrity of BBB capillary endothelial cells and cause structural failure (25) .
However, our molecular findings [disproportionate exchange of LO cannot exclude "focal" hypoxemia and perturbed metabolism due to perfusion/diffusion heterogeneity especially in areas of the brain that are exquisitely sensitive to hypoxia such as the CA1 neurons, the corpus striatum and Purkinje cells of the cerebellum (35) . However, what is clear from our data is that a decrease in global CMRO 2 is neither the cause nor consequence of AMS.
PERSPECTIVES AND SIGNIFICANCE
In support of our original hypothesis, these findings are the first to demonstrate a net transcerebral output of oxidative-nitrative stress agents during hypoxia. This has broader implications for other clinical models of human disease characterized by systemic arterial hypoxemia and identifies the (hypoxic) human brain as a potential source of vascular injury and SIRS in the critically ill. The consistent relationships observed between the net cerebral output of free radicals and symptom scores, while not disassociating cause from effect, also suggests that cerebral oxidative-nitrative stress may be a potential risk factor for AMS. Contrary to widespread speculation implicating vasogenic edema as a significant pathogenic event, our molecular findings suggest that the underlying mechanism is likely independent of BBB disruption and impaired global cerebral oxidative metabolism. Finally, our findings provide ethical justification for follow-up interventional studies incorporating neuro-antioxidant prophylaxis to determine if redox-activation of the TVS does indeed represent the "final common pathway" in AMS. normoxia for given sample site (P < 0.05). Table 4 . Values are mean ± SD; NSE, neuron specific enolase. 
